Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset

October 04, 2023 By The ASCO Post Staff

Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this population.

Related Content